Related Experiment Video
Updated: Jul 19, 2025
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
19.7K
Unusual Extreme Leukocytosis in Metformin Overdose
Daniela Radulescu1, Elena Cuiban1,2, Ileana Adela Vacaroiu1,2
1Clinical Department No. 3, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Maedica
|August 17, 2023
Summary
Metformin overdose can cause a falsely high white blood cell count due to leukocyte demargination, not infection. This highlights the need for careful diagnosis in stressful conditions to avoid unnecessary antibiotics.
Area of Science:
- Clinical Medicine
- Toxicology
- Hematology
Background:
- Presents a case of extreme leukocytosis, severe lactic acidosis, and acute kidney injury in a patient with metformin overdose.
- Investigated potential infectious or malignant etiologies for the elevated leukocyte count.
Discussion:
- Explores leukocyte demargination as the primary cause of leukocytosis in this non-infectious, acute stress scenario.
- Reviews relevant literature on spurious leukocytosis in critical illness.
Key Insights:
- Metformin overdose can induce significant leukocytosis through leukocyte demargination.
- Distinguishing spurious leukocytosis from true infection is crucial for appropriate patient management.
- Highlights the importance of considering non-infectious causes of leukocytosis in critically ill patients.
Outlook:
- Emphasizes the need for clinicians to recognize spurious leukocytosis to prevent unnecessary antibiotic administration.
- Suggests further research into the mechanisms and clinical implications of stress-induced leukocytosis.
Related Concept Videos
01:27Disorders of Leukocytes
982
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
982
01:15Hypoglycemia and Glucagon
296
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
296
01:20Inborn Errors of Metabolism
194
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
194
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
195
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
195
01:22Nonlinear Pharmacokinetics: Causes of Nonlinearity
233
Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
233